AU2012293646B2 - New antibodies against phosphorylcholine - Google Patents

New antibodies against phosphorylcholine Download PDF

Info

Publication number
AU2012293646B2
AU2012293646B2 AU2012293646A AU2012293646A AU2012293646B2 AU 2012293646 B2 AU2012293646 B2 AU 2012293646B2 AU 2012293646 A AU2012293646 A AU 2012293646A AU 2012293646 A AU2012293646 A AU 2012293646A AU 2012293646 B2 AU2012293646 B2 AU 2012293646B2
Authority
AU
Australia
Prior art keywords
sequence
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012293646A
Other languages
English (en)
Other versions
AU2012293646A1 (en
AU2012293646A8 (en
Inventor
Ola Camber
Andrew E NIXON
Knut Pettersson
Dan SEXTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athera Biotechnologies AB
Dyax Corp
Original Assignee
Athera Biotechnologies AB
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies AB, Dyax Corp filed Critical Athera Biotechnologies AB
Publication of AU2012293646A1 publication Critical patent/AU2012293646A1/en
Publication of AU2012293646A8 publication Critical patent/AU2012293646A8/en
Application granted granted Critical
Publication of AU2012293646B2 publication Critical patent/AU2012293646B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
AU2012293646A 2011-08-09 2012-08-08 New antibodies against phosphorylcholine Ceased AU2012293646B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521593P 2011-08-09 2011-08-09
US61/521,593 2011-08-09
PCT/EP2012/065505 WO2013020995A1 (en) 2011-08-09 2012-08-08 New antibodies against phosphorylcholine

Publications (3)

Publication Number Publication Date
AU2012293646A1 AU2012293646A1 (en) 2014-02-20
AU2012293646A8 AU2012293646A8 (en) 2014-03-06
AU2012293646B2 true AU2012293646B2 (en) 2017-08-31

Family

ID=46679261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012293646A Ceased AU2012293646B2 (en) 2011-08-09 2012-08-08 New antibodies against phosphorylcholine

Country Status (28)

Country Link
US (3) US9803028B2 (enExample)
EP (1) EP2742068B1 (enExample)
JP (1) JP6277125B2 (enExample)
KR (1) KR101947758B1 (enExample)
CN (1) CN104039832B (enExample)
AR (1) AR087485A1 (enExample)
AU (1) AU2012293646B2 (enExample)
BR (1) BR112014002929A8 (enExample)
CA (1) CA2843921A1 (enExample)
CY (1) CY1121950T1 (enExample)
DK (1) DK2742068T3 (enExample)
ES (1) ES2732838T3 (enExample)
HK (1) HK1200852A1 (enExample)
HR (1) HRP20190988T1 (enExample)
HU (1) HUE045163T2 (enExample)
LT (1) LT2742068T (enExample)
MX (1) MX364425B (enExample)
PL (1) PL2742068T3 (enExample)
PT (1) PT2742068T (enExample)
RS (1) RS58986B1 (enExample)
RU (1) RU2654584C2 (enExample)
SG (1) SG2014009344A (enExample)
SI (1) SI2742068T1 (enExample)
SM (1) SMT201900366T1 (enExample)
TR (1) TR201909072T4 (enExample)
TW (1) TWI707873B (enExample)
WO (1) WO2013020995A1 (enExample)
ZA (1) ZA201400665B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
SI2742068T1 (sl) * 2011-08-09 2019-08-30 Athera Biotechnologies Ab Nova protitelesa proti fosforilholinu
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US20180066262A1 (en) 2015-03-09 2018-03-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. THERAPEUTIC OLIGONUCLEOTIDES
EP3328873B1 (en) 2015-07-28 2025-09-17 Caris Science, Inc. Targeted oligonucleotides
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100405A2 (en) * 2004-04-15 2005-10-27 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
WO2010003602A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE3751182T2 (de) 1986-08-06 1995-10-26 Scripps Clinic Res Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
WO1990012632A1 (en) 1989-04-19 1990-11-01 The United States Of America, Represented By The Secretary, United States Department Of Commerce Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
EP0562020A4 (en) 1990-12-10 1993-11-18 Alving, Carl L. A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
RU2014609C1 (ru) * 1991-06-06 1994-06-15 Московский институт тонкой химической технологии им.М.В.Ломоносова Способ определения белков, специфичных к фосфорилхолину
EP0631624A1 (en) 1992-03-03 1995-01-04 The Rockefeller University Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en) 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
AU6268894A (en) 1993-02-22 1994-09-14 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
AU1159497A (en) 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
ES2205853T3 (es) 1998-07-03 2004-05-01 Athera Biotechnologies Ab Metodo para diagnosticar la enfermedad cardiovascular y la aterosclerosis precoz.
JP2003513027A (ja) 1999-10-26 2003-04-08 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア アテローム性動脈硬化症の診断、結像、治療用の薬剤及びその方法
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
AU2001259730A1 (en) 2000-05-12 2001-11-26 The Regents Of The University Of California Standardized oxidized ldl assay
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20070122419A1 (en) 2003-04-11 2007-05-31 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP5122908B2 (ja) 2007-10-17 2013-01-16 日泉化学株式会社 自動車の内装用部材の取り付け構造
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
KR102502293B1 (ko) * 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
SI2742068T1 (sl) * 2011-08-09 2019-08-30 Athera Biotechnologies Ab Nova protitelesa proti fosforilholinu
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100405A2 (en) * 2004-04-15 2005-10-27 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
WO2010003602A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHANG et al., PNAS, 1999, Vol. 96, Pages 6353-6358. *
De FAIRE et al. "Natural Antibodies against Phosphorylcholine in Cardiovascular Disease", Contemporary Challenges in Autoimmunity: Annals of the New York Academy of Sciences, 2009, Vol. 1173, Pages 292–300. *
Ewing et al., Circulation, 2010, Vol. 122, Issue Suppl. 21, Abstract 14320. *
HORKKO et al., The Journal of Clinical Investigation, 1999, Vol. 103, No. 1, Pages 117-128. *
PLUCKTHUN et al. "Comparison of the Fv Fragments of Different Phosphorylcholine Binding Antibodies Expressed in Escherichia coli", Annals of the New York Academy of Sciences, 1991, Vol. 646, Pages 115-124. *
SCHMIDT et al. "Out-licensing: A start-up Company Perspective", Athera Biotechnologies, 2009, Slides 1-21. *
SHAW et al. "Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity", The Journal of Clinical Investigation, 2000, Vol. 105, No. 12, Pages 1731-1740. *

Also Published As

Publication number Publication date
MX2014001313A (es) 2014-07-28
PL2742068T3 (pl) 2020-01-31
LT2742068T (lt) 2019-07-10
US20140178410A1 (en) 2014-06-26
WO2013020995A1 (en) 2013-02-14
JP2014525233A (ja) 2014-09-29
CN104039832A (zh) 2014-09-10
SI2742068T1 (sl) 2019-08-30
HK1200852A1 (en) 2015-08-14
US20210238311A1 (en) 2021-08-05
US9803028B2 (en) 2017-10-31
HRP20190988T1 (hr) 2019-09-20
CN104039832B (zh) 2021-02-12
ZA201400665B (en) 2019-08-28
TWI707873B (zh) 2020-10-21
SMT201900366T1 (it) 2019-07-11
PT2742068T (pt) 2019-07-08
DK2742068T3 (da) 2019-06-11
ES2732838T3 (es) 2019-11-26
EP2742068B1 (en) 2019-04-03
HUE045163T2 (hu) 2019-12-30
AR087485A1 (es) 2014-03-26
CY1121950T1 (el) 2020-10-14
AU2012293646A1 (en) 2014-02-20
TW201321415A (zh) 2013-06-01
SG2014009344A (en) 2014-07-30
AU2012293646A8 (en) 2014-03-06
RU2014108815A (ru) 2015-09-20
BR112014002929A8 (pt) 2021-09-28
KR101947758B1 (ko) 2019-02-14
KR20140068948A (ko) 2014-06-09
MX364425B (es) 2019-04-25
BR112014002929A2 (pt) 2017-03-28
US20180086848A1 (en) 2018-03-29
EP2742068A1 (en) 2014-06-18
TR201909072T4 (tr) 2019-08-21
RU2654584C2 (ru) 2018-05-21
JP6277125B2 (ja) 2018-02-07
RS58986B1 (sr) 2019-08-30
CA2843921A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
US20210238311A1 (en) Antibodies against phosphorylcholine
US20210230310A1 (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
AU2015270480B2 (en) Compositions for inhibiting MASP-2 dependent complement activation
HK1199409B (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 7 , PAGE(S) 951 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ATHERA BIOTECHNOLOGIES AB; YAX CORP., APPLICATION NO. 2012293646, UNDER INID (71) CORRECT CO-APPLICANT NAME TO DYAX CORP.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired